The company announced the closing of its underwritten public offering of 21,131,250 common shares, without par value, which included the underwriters exercising their option to purchase an additional 2,756,250 common shares at a public offering price of US$12.25 per common share. Hogan Lovells advised Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company developing product candidates to treat brain health disorders.